Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation

Amgen and Array BioPharma today announced a collaboration agreement for the discovery and development of novel drugs for autoimmune disorders. The undisclosed target and lead inhibitors were discovered through Array's proprietary platform that leverages Array's expertise in chemistry and early lead development. We are pleased to enter this collaboration with Array that builds on our continued focus in inflammation, one of Amgen's key strategic areas of interest," said Flavius Martin, M.D., vice president of Research, Inflammation and Oncology at Amgen. "We look forward to partnering with Array BioPharma to advance molecules into the clinic that may offer a new treatment option for patients.